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1. INTRODUCTION {#dad212042-sec-0050}
===============

With the growing prevalence of dementia globally, timely detection of neurodegenerative disease is critical for optimizing treatment and care plans. Cognitive assessments play a key role in the accurate diagnosis and monitoring of Alzheimer\'s disease and related disorders (ADRD).[^1^](#dad212042-bib-0001){ref-type="ref"}, [^2^](#dad212042-bib-0002){ref-type="ref"} Additionally, numerous studies have shown that the presence of neurodegenerative pathology, such as amyloid plaques in Alzheimer\'s disease (AD), precedes clinical manifestation of dementia,[^3^](#dad212042-bib-0003){ref-type="ref"}, [^4^](#dad212042-bib-0004){ref-type="ref"} and amyloid‐positive subjects are at a greater risk of longitudinal cognitive decline.[^5^](#dad212042-bib-0005){ref-type="ref"}, [^6^](#dad212042-bib-0006){ref-type="ref"} Thus, cognitive measures capable of estimating longitudinal cognitive changes may be particularly sensitive to an underlying neurodegenerative etiology in preclinical stages of the disease.[^3^](#dad212042-bib-0003){ref-type="ref"}, [^4^](#dad212042-bib-0004){ref-type="ref"}

Brief measures of cognition that can be feasibly repeated at subsequent visits are well suited for the detection of meaningful cognitive change because they minimize time and other resource costs compared to traditional neuropsychological tests. Of the variety of brief cognitive measures available, the most commonly used, the Mini‐Mental State Examination (MMSE[^7^](#dad212042-bib-0007){ref-type="ref"}), has well‐documented ceiling effects limiting its sensitivity to change over time, especially during preclinical or prodromal disease stages.[^8^](#dad212042-bib-0008){ref-type="ref"} At the same time, the MMSE is characterized by a particular strength in that it provides a composite score capturing performance across multiple cognitive domains, which enhances its predictive validity given the variability of cognitive deficits associated with neurodegenerative disease.[^9^](#dad212042-bib-0009){ref-type="ref"} Moreover, the utility of the cognitive composite measures for clinical trials has been supported by the U.S. Food and Drug Administration[^10^](#dad212042-bib-0010){ref-type="ref"} due to their potential effectiveness in monitoring progression of symptoms over time and evaluating treatment effects.[^2^](#dad212042-bib-0002){ref-type="ref"}, [^11^](#dad212042-bib-0011){ref-type="ref"}

Several other psychometrically sound composite scores have been developed for ADRD, including the cognitive subscale of the Alzheimer\'s Disease Assessment Scale (ADAS‐Cog[^12^](#dad212042-bib-0012){ref-type="ref"}), the Alzheimer\'s Prevention Initiative composite cognitive test score,[^13^](#dad212042-bib-0013){ref-type="ref"} and the Preclinical Alzheimer Cognitive Composite,[^14^](#dad212042-bib-0014){ref-type="ref"} among others. These metrics are derived from a broader range of cognitive measures tapping into several cognitive domains, thus making them more sensitive to heterogeneity of presentations seen in ADRD.[^15^](#dad212042-bib-0015){ref-type="ref"} However, most of these composites were developed based on traditional paper‐and‐pencil measures and require administration by highly trained clinicians or psychometricians, limiting their wide‐scale application. Additionally, concerns have been raised regarding the feasibility of such measures for repeated use due to the fact that these instruments rely on rather lengthy cognitive batteries.[^15^](#dad212042-bib-0015){ref-type="ref"} Computerized cognitive measures offer advantages over existing measures because they can reduce error associated with administration variability, automate scoring and interpretation, provide easy access to alternate forms, and offer efficiency of staffing and cost.[^16^](#dad212042-bib-0016){ref-type="ref"} Like their traditional counterparts, these measures must be comprised of constituent tasks that evaluate the spectrum of cognitive changes seen in typical and less typical neurodegenerative syndromes for sensitive detection of decline.[^15^](#dad212042-bib-0015){ref-type="ref"}

RESEARCH IN CONTEXT {#dad212042-sec-0060}
-------------------

Systematic review: We reviewed the literature on use of cognitive composite scores for early detection of neurodegenerative diseases using traditional sources (eg, PubMed). While several composite metrics have been described, there are ongoing efforts to develop more psychometrically robust and sensitive composites for use in clinical practice and drug trials.Interpretation: Our findings showed that a novel cognitive composite based on a brief computerized battery accurately detected cognitive decline across the spectrum of preclinical and early stage neurodegenerative disease.Future directions: Additional validation of the composite score in culturally diverse populations is needed.

In this study, we developed and validated the Brain Health Assessment‐Cognitive Score (BHA‐CS), a composite score based on a brief tablet‐based battery that efficiently measures associative memory, executive function and speed, language generation, and visuospatial skills, and was previously shown to exhibit high accuracy for detecting mild cognitive impairment (MCI) and dementia.[^17^](#dad212042-bib-0017){ref-type="ref"} We also evaluated its long‐term stability and estimated reliable change in cognitively normal (CN) older adults and individuals with MCI and dementia at 1‐year follow‐up. Finally, we investigated longitudinal sensitivity of the BHA‐CS to early AD biomarkers based on amyloid beta (Aβ)‐positron emission tomography (PET) in CN older adults over 3‐year follow‐up. Across all analyses, we compared the performance of the BHA‐CS to the reference brief assessment, the Montreal Cognitive Assessment (MoCA[^18^](#dad212042-bib-0018){ref-type="ref"}). We selected the MoCA as the reference for comparison as it has been reported to be sensitive to cognitive changes in mild stages of cognitive decline.[^19^](#dad212042-bib-0019){ref-type="ref"}, [^20^](#dad212042-bib-0020){ref-type="ref"}

2. METHODS {#dad212042-sec-0070}
==========

2.1. Participants {#dad212042-sec-0080}
-----------------

The study was approved by the University of California San Francisco (UCSF) Committee on Human Research and the University of California Davis (UCD) Institutional Review Board. All participants provided written informed consent. Subjects were English‐ or Spanish‐speaking adults aged 50 or above recruited from longitudinal observational studies at the UCSF Memory and Aging Center and the UCD Alzheimer\'s Disease Center. All participants including CN were diagnosed in multidisciplinary clinical consensus conferences based on neurological and neuropsychological examination, clinical interview with an informant including Clinical Dementia Rating (CDR[^21^](#dad212042-bib-0021){ref-type="ref"}), and structural neuroimaging.[^17^](#dad212042-bib-0017){ref-type="ref"} This clinical diagnostic work‐up was completed at all baseline and follow‐up visits. Exclusion criteria included severe psychiatric illness, other non‐neurodegenerative neurological condition that could affect cognition, substance use disorder diagnosed in the last 20 years, significant systemic illness, and presence of subjective cognitive concerns or CDR Global Score \>0 for CN. Diagnoses of MCI and dementia were made based on published criteria as previously described.[^17^](#dad212042-bib-0017){ref-type="ref"}

The BHA‐CS was developed and cross‐validated in a sample of 451 CN, 289 MCI, and 110 mild dementia participants who completed the BHA tests and the MoCA at baseline in English or Spanish. Long‐term stability and reliable change estimations were evaluated in the subset of participants who completed the BHA (265 CN, 59 MCI, 16 dementia) and the MoCA (251 CN, 50 MCI, 14 dementia) at baseline and at 1‐year follow‐up visits. Finally, examination of the association between Aβ burden and longitudinal changes on the BHA‐CS and the MoCA was based on the subset of CN older adults who completed the BHA (N = 119; 90 Aβ−, 29 Aβ+) and the MoCA (N = 117; 89 Aβ−, 28 Aβ+) at two or more follow‐up visits over the course of 3 years and also underwent Aβ‐PET imaging and apolipoprotein E (*APOE*) genotyping.

2.2. Measures and procedure {#dad212042-sec-0090}
---------------------------

### 2.2.1. Cognitive tests {#dad212042-sec-0100}

The BHA is programmed in the TabCAT software platform (UCSF, San Francisco, CA) and consists of four subtests: Favorites (associative memory), Match (executive functioning and processing speed), Line Orientation (visuospatial skills), and Animal Fluency (language).[^17^](#dad212042-bib-0017){ref-type="ref"} Detailed task descriptions and Spanish adaptation are provided in the supporting information and memory.ucsf.edu/tabcat. Testing time is 10 minutes. The MoCA is a widely used cognitive screen assessing the following domains: visuoconstruction and executive functions, attention, language, abstraction, memory, and orientation, and also takes ≈10 minutes to administer.[^18^](#dad212042-bib-0018){ref-type="ref"} The total score is calculated as a sum of points across domains with a maximum of 30 points. All participants completed the BHA tests and the MoCA in a private examination room independent of diagnostic assessments. For the BHA administration, participants were seated in a chair at a desk with a 9.7‐inch iPad positioned horizontally in front of them, with the back of the tablet propped 1 inch up from the surface of the desk. An administrator sat next to the participant. The MoCA was administered in a standardized fashion in accordance with original instructions.[^18^](#dad212042-bib-0018){ref-type="ref"}

### 2.2.2. Neuroimaging and *APOE* genotyping {#dad212042-sec-0110}

Aβ imaging was based on PET with 18F‐Florbetapir acquired at UCSF China Basin on a GE Discovery STE/VCT PET‐CT scanner. Data acquisition and processing was performed in accordance with the Alzheimer\'s Disease Neuroimaging Initiative protocol[^22^](#dad212042-bib-0022){ref-type="ref"} (for details, see supporting information). To determine Aβ‐PET positivity, we applied a 1.11 standardized uptake value ratio (SUVR) threshold derived from previous publications using identical acquisition parameters and pre‐processing pipelines.[^23^](#dad212042-bib-0023){ref-type="ref"}, [^24^](#dad212042-bib-0024){ref-type="ref"} *APOE* genotyping was based on DNA analysis from peripheral blood samples as described previously.[^25^](#dad212042-bib-0025){ref-type="ref"} *APOE* ε4 status was dummy coded as "1″ for homozygotes and heterozygotes of ε4 and "0″ otherwise. There were no participants with ε2/ε4 genotype in the sample.

2.3. Statistical analyses {#dad212042-sec-0120}
-------------------------

### 2.3.1. BHA‐CS construction and validation {#dad212042-sec-0130}

The BHA‐CS was defined as the sum of weighted demographically adjusted scaled scores of BHA component tests. The weights for each of the component tests were logistic regression parameter estimates derived on the basis of a model discriminating cognitively intact and cognitively impaired (MCI or dementia) participants. First, the raw scores of individual subtests were transformed to *z*‐scores using regression‐based normative adjustments for age, education, sex, and language (see supporting information). Then, we built a logistic regression model in which predictors were demographically adjusted *z*‐scores of the BHA subtests, and the outcome was a dichotomized cognitive status variable. All predictors were entered in the model simultaneously, and non‐significant predictors were excluded in a stepwise fashion. The derived BHA‐CS scores were then scaled to the mean and standard deviation of the CN group.

We used a repeated 3 × 5‐fold cross‐validation to estimate the out‐of‐sample accuracy of the BHA‐CS model.[^26^](#dad212042-bib-0026){ref-type="ref"} The key feature of repeated cross‐validation procedures is that they test the effectiveness of the model derived from one part of the dataset (training set) on the reserved part of the dataset (validation set). In our analyses, the cross‐validation algorithm divided the dataset into five equally sized random subsets with grossly proportional number of CN and cognitively impaired subjects in each subset and treated each of the subsets as a validation set while the other four were treated as a training set. This procedure was repeated three times based on random permutations. The results were based on the average overall accuracy and average sensitivity and specificity metrics per permutation.

### 2.3.2. Long‐term test stability and reliable change indices {#dad212042-sec-0140}

To examine long‐term stability, we calculated correlation coefficients (Pearson\'s *r*) across two visits. These analyses estimate overall reliability of the scores at 1‐year follow‐up. Based on existing literature,[^27^](#dad212042-bib-0027){ref-type="ref"}, [^28^](#dad212042-bib-0028){ref-type="ref"} we applied the most conservative approaches to reliable change indices (RCI) estimates given the psychometric properties of each measure. The purpose of RCI estimation is to evaluate whether a statistically significant change in test‐retest scores has occurred beyond the effects of systematic or measurement errors, such as practice effects, low reliability of the test, or regression to the mean.[^28^](#dad212042-bib-0028){ref-type="ref"} For the BHA‐CS, upper and lower 90% RCI were calculated using a standardized regression‐based approach,[^29^](#dad212042-bib-0029){ref-type="ref"} whereby the predicted follow‐up performance score (derived from multiple regression using the baseline score, age, sex, education, and retest interval as predictors) is subtracted from the actual follow‐up score, and the difference is standardized based on the standard error of the estimate of the regression equation. Predictors were removed from the model in a stepwise fashion with only significant predictors included in the final model. For the MoCA, 90% RCI were derived based on a formula of the difference between follow‐up and baseline scores corrected for practice effects and the standardized error of difference[^30^](#dad212042-bib-0030){ref-type="ref"} in light of well‐documented ceiling effects of the measure and deviation from regression assumptions based on existing studies.[^31^](#dad212042-bib-0031){ref-type="ref"}, [^32^](#dad212042-bib-0032){ref-type="ref"} Reliable improvement or decline was defined as RCI values greater than ± 1.645 based on a two‐tailed prediction with *α* set at .05. Independent sample t‐tests were performed to examine group differences on RCI on both instruments.

### 2.3.3. Association with Aβ burden in healthy older adults {#dad212042-sec-0150}

Linear mixed effect models using maximum likelihood estimation with random intercepts were used to investigate the relationship between baseline Aβ status and cognitive change in CN subjects. The main model included continuous Aβ SUVR values, time (years since baseline), and SUVR × time interaction to investigate changes on the BHA‐CS and the MoCA. The covariates included were baseline age (centered), sex, education, *APOE* ε4, and the random effect of cognitive score intercepts. We also examined the *APOE* ε4 × time and age × time interactions to ensure that the changes on cognitive measures over time were not explained by *APOE* or age variables. The supporting models were analogous to the main one but included a dichotomized Aβ status (positive vs negative) instead of a continuous SUVR as a predictor.

All analyses were performed in R (v3.6.0, R Project for Statistical Computing) with two‐tailed significance level set at *P *\< .05. We used the caret package (v6.0‐84)[^33^](#dad212042-bib-0033){ref-type="ref"} for cross‐validation analysis, lme4 package (v1.1‐21)[^34^](#dad212042-bib-0034){ref-type="ref"} for estimation of linear mixed effects models, and ggplot2 (v3.1.1)[^35^](#dad212042-bib-0035){ref-type="ref"} package for generating figures and plots.

3. RESULTS {#dad212042-sec-0160}
==========

3.1. Demographics {#dad212042-sec-0170}
-----------------

Baseline demographic characteristics of the BHA‐CS validation sample are presented in Table [1](#dad212042-tbl-0001){ref-type="table"}. The CN group was younger, included more women, and had higher education compared to the MCI and dementia groups. Detailed description of the cognitively impaired sample based on clinical syndromes is presented in supporting information. Baseline demographic characteristics of the Spanish‐speaking subsample and the follow‐up subsamples, which were subsets of the validation sample used to evaluate long‐term stability and associations with Aβ burden, are provided in Tables S1‐S3 in supporting information. At follow‐up, there were no significant differences between the CN and cognitively impaired groups on any of the demographic characteristics, including age, education, sex, or race/ethnicity (Table S2). Similarly, Aβ+ and Aβ− CN groups did not differ in age, sex, education, race, or prevalence of *APOE* ε4 status at baseline or at follow‐up (Table S3).

###### 

Baseline demographic characteristics and group differences (N = 850)

                              CN (N = 451)   MCI (N = 289)   Dementia (N = 110)   *P* value[^\*^](#dad212042-tbl1-note-0003){ref-type="fn"}
  --------------------------- -------------- --------------- -------------------- -----------------------------------------------------------
  Age, years                  73.3 ± 8.2     71.1 ± 8.8      70.6 ± 10.2          \<.001
  Education, years            17.0 ± 2.5     16.4 ± 3.1      15.7 ± 2.8           \<.001
  Female, n (%)               268 (59%)      128 (44%)       45 (41%)             \<.001
  White non‐Hispanic, n (%)   346 (77%)      238 (82%)       90 (82%)             .303
  CDR total                   0 ± 0          0.5 ± 0.2       1.1 ± 0.4            \<.001
  MMSE                        29.1 ± 1.1     26.5 ± 2.9      22.5 ± 4.6           \<.001
  MoCA                        26.6 ± 2.3     22.4 ± 4.3      17.1 ± 5.2           \<.001

Abbreviations: CDR, Clinical Dementia Rating; CN, cognitively normal; MCI, mild cognitive impairment; MMSE, Mini‐Mental State Examination; MoCA, Montreal Cognitive Assessment.

Values are presented as means ± standard deviations unless otherwise indicated.

Based on differences between MCI and dementia relative to CN and estimated from t‐tests for continuous variables or Pearson\'s χ^2^ tests for categorical variables.

John Wiley & Sons, Ltd.

3.2. BHA‐CS validation {#dad212042-sec-0180}
----------------------

The results of the logistic regression analysis revealed statistically significant contributions of three of the four BHA subtests: Favorites, Match, and Animal Fluency (Table [2](#dad212042-tbl-0002){ref-type="table"}). Therefore, the composite metric was expressed as BHA‐CS = (\[*a* + *b~Favorites~z~Favorites~* + *b~Match~z~Match~* + *b~AnimalFluency~z~AnimalFluency~*\] -- *M~CN~*)/*SD~CN~*, where *a* is the intercept of the regression equation; *b* is unstandardized parameter estimates for Favorites, Match, and Animal Fluency subtests, respectively; *z* is demographically corrected *z*‐scores of Favorites, Match, and Animal Fluency subtests, respectively; and *M~CN~* and *SD~CN~* are the mean and standard deviation of the BHA‐CS in CN, respectively. The final formula for the BHS‐CS was: BHA‐CS = (\[1.839 + 0.824\**z~Favorites~* + 0.858\**z~Match~* + 0.489\**z~AnimalFluency~*\] −  1.837)/1.516.

###### 

Summary of the logistic regression model for development of the BHA‐CS

                             B       SE      *z* value   *P* value
  -------------------------- ------- ------- ----------- -----------
  Intercept                  1.839   0.145   12.67       \<.001
  Favorites *z*‐score        0.824   0.100   8.21        \<.001
  Match *z*‐score            0.858   0.100   8.61        \<.001
  Animal fluency *z*‐score   0.489   0.105   4.67        \<.001

Abbreviations: B, unstandardized regression estimate; BHA‐CS, Brain Health Assessment‐Cognitive Score; SE, standard error.

John Wiley & Sons, Ltd.

In the validation sample, 83% of cognitively impaired subjects and 15% of CN subjects had a BHA‐CS of \<−1.0, while 85% of CN participants and 17% of cognitively impaired subjects had a BHA‐CS score of −1.0 or above. Receiver operating characteristic (ROC) analyses were consistent with previously reported results[^17^](#dad212042-bib-0017){ref-type="ref"} and suggested that the BHA‐CS accurately discriminated cognitively intact and cognitively impaired subjects (Figure S1 in supporting information). Results of the cross‐validation analysis revealed an overall accuracy of .85 (95% confidence interval \[CI\]: .82‐.87), sensitivity of .88, and specificity of .80. When specificity was set at .85, sensitivity was .83. Analogous preliminary results in the Spanish‐speaking group, while limited by a small sample size, suggested that the BHA‐CS was similarly accurate at detecting cognitive impairment among Spanish speakers with an overall accuracy of .83 (95% CI: .69‐.93), sensitivity of .95, and specificity of .71. When specificity was set at .85, sensitivity was .81 in the Spanish‐speaking sample.

3.3. Long‐term stability and reliable change indices {#dad212042-sec-0190}
----------------------------------------------------

Long‐term stability at 1‐year follow‐up on the BHA‐CS was excellent in the whole sample (*r* = .89, 95% CI: .85‐.91) and weaker when restricted to the CN group (*r* = .70, 95% CI: .62‐.77). MoCA demonstrated poorer stability indices both in the whole sample (*r* = .75, 95% CI: .70‐.80) and in the CN group only (*r* = .50, 95% CI: .40‐.59). Significant predictors of the BHA‐CS follow‐up score were baseline score and baseline age, such that lower baseline score and older age were associated with more decline, while sex, education, and retest interval were not significant (Table S4 in supporting information). The average practice effect on the BHA‐CS was 0.2 (Table S2).

Comparing BHA‐CS reliable change indices, both MCI (*t* = −9.04, *P *\< .001) and mild dementia (*t* = −5.83, *P* = \< .001) groups showed greater rates of decline over time compared to CN. Similar results were observed on the MoCA, although the effect sizes were smaller in both MCI (*t* = −2.80, *P* = .007) and mild dementia (*t* = −2.03, *P* = .062) compared to CN. The frequency rates of reliable change estimates across diagnostic groups are presented in Table [3](#dad212042-tbl-0003){ref-type="table"}.

###### 

Rates of reliable change at 1‐year follow‐up visits on the BHA‐CS and the MoCA across diagnostic groups

                                                                   Declined, n (%)   Stable, n (%)   Improved, n (%)
  ---------- ----------------------------------------------------- ----------------- --------------- -----------------
  CN                                                                                                 
             BHA‐CS                                                8/265 (3%)        249/265 (94%)   8/265 (3%)
             MoCA                                                  16/251 (6%)       226/251 (90%)   9/251 (4%)
  MCI                                                                                                
             BHA‐CS                                                26/59 (44%)       33/59 (56%)     0/59 (0%)
             MoCA                                                  10/50 (20%)       38/50 (76%)     2/50 (4%)
  Dementia                                                                                           
             BHA‐CS                                                12/16 (75%)       4/16 (25%)      0/16 (0%)
             MoCA[^a^](#dad212042-tbl3-note-0002){ref-type="fn"}   3/14 (21%)        10/14 (71%)     1/14 (7%)

Abbreviations: BHA‐CS, Brain Health Assessment‐Cognitive Score; CN, cognitively normal; MCI, mild cognitive impairment; MoCA, Montreal Cognitive Assessment.

Percentages do not add to 100 due to rounding.

John Wiley & Sons, Ltd.

3.4. Associations with Aβ burden in CN {#dad212042-sec-0200}
--------------------------------------

No significant differences between Aβ+ and Aβ− groups were observed at baseline, second, or third follow‐up visits on the MoCA scores (Table S3). On the BHA, Aβ+ group had significantly lower scores than Aβ− group at the third visit (Table S3). Results of the linear mixed effect models showed that greater Aβ SUVR at baseline was associated with poorer performance on the BHA‐CS over time (B = −0.957, SE = 0.221, *P *\< .001; Table [4](#dad212042-tbl-0004){ref-type="table"}). The SUVR × time interaction estimates remained significant after inclusion of *APOE* ε4 × time (B = −0.862, SE = 0.231, *P *\< .001) and age × time (B = −0.948, SE = 0.218, *P *\< .001) interaction terms in the model (Tables S5 and S6 in supporting information). Similar results were observed when a dichotomous Aβ status × time interaction was tested with the main effect of Aβ+ group showing poorer performance over time on the BHA‐CS compared to the Aβ− group (B = −0.250, SE = 0.061, *P *\< .001; Table S7 in supporting information). On the MoCA, neither the continuous (*P* = .630, Table [4](#dad212042-tbl-0004){ref-type="table"}) nor dichotomous Aβ × time interactions (*P* = .483, Table S7) were significant. Figure [1](#dad212042-fig-0001){ref-type="fig"} depicts trajectories of change over time as a function of baseline dichotomous Aβ status while holding all other fixed effects constant on the BHA‐CS and the MoCA (based on Table S7).

###### 

Summary of the linear mixed effect models with baseline continuous amyloid beta × time interaction on the BHA‐CS and the MoCA in CN (N = 119)

                   BHA‐CS   MoCA                              
  ---------------- -------- ------- -------- -------- ------- --------
  Intercept        0.300    1.244   .810     25.906   1.683   \<.001
  Baseline age     −0.007   0.013   .601     −0.082   0.026   .002
  Female sex       0.154    0.158   .332     0.257    0.317   .418
  *APOE ε4*        0.127    0.195   .514     0.537    0.390   .171
  Aβ SUVR          0.452    0.739   .542     0.852    1.585   .592
  Time             1.099    0.234   \<.001   0.380    0.669   .571
  Aβ SUVR × time   −0.957   0.221   \<.001   −0.303   0.628   630

Abbreviations: *APOE*, apolipoprotein E; Aβ, amyloid beta; B, unstandardized regression estimate; BHA‐CS, Brain Health Assessment‐Cognitive Score; CN, cognitively normal; MoCA, Montreal Cognitive Assessment; SE, standard error; SUVR, standardized uptake value ratio.

John Wiley & Sons, Ltd.

![Predicted longitudinal performance on the Brain Health Assessment‐Cognitive Score and the Montreal Cognitive Assessment in cognitively normal older adults by dichotomous amyloid beta status](DAD2-12-e12042-g001){#dad212042-fig-0001}

4. DISCUSSION {#dad212042-sec-0210}
=============

Psychometrically robust and sensitive measures of cognition are critical for early detection and monitoring of progression of neurodegenerative disease. Cognitive outcomes measured by multidomain composite scores have been shown to be particularly well suited to serve this purpose and to be more sensitive to preclinical changes compared to single domain metrics.[^36^](#dad212042-bib-0036){ref-type="ref"}, [^37^](#dad212042-bib-0037){ref-type="ref"} The BHA‐CS, a cognitive composite measure optimized for the detection of cognitive impairment, is derived from brief tests of associative episodic memory, executive function and processing speed, and semantic fluency. These domains have been consistently shown to be affected early in a neurodegenerative process due to AD.[^38^](#dad212042-bib-0038){ref-type="ref"} The novel measures that contributed most significantly to the BHA‐CS composite were Match (executive functions and speed) and Favorites (episodic memory), which may be related to their widespread neural bases in brain regions frequently affected in neurodegenerative disease. Specifically, we previously showed that performance on Match was strongly correlated with gray matter volumes in bilateral frontal, parietal, and subcortical regions, and white matter integrity in the corpus callosum.[^17^](#dad212042-bib-0017){ref-type="ref"}, [^39^](#dad212042-bib-0039){ref-type="ref"} Similarly, performance on Favorites localized to gray matter volumes in bilateral temporal, insular, and frontal regions with most significant associations with medial temporal lobes.[^17^](#dad212042-bib-0017){ref-type="ref"} In contrast, performance on Line Orientation, which did not significantly contribute to the BHA‐CS composite, narrowly localized to a cluster of gray matter in the right superior parietal lobe.[^17^](#dad212042-bib-0017){ref-type="ref"} While this region represents an important area for diagnosis of neurodegenerative syndromes, it may not have predicted unique variance in cognitive impairment status due to its overlapping neural basis with Match.

Our analyses indicated greater sensitivity of the BHA‐CS to change over time in the prodromal (MCI) stage of neurodegenerative disease compared to the commonly used MoCA. These results are particularly relevant to clinical settings, where robust cognitive change estimations may inform diagnostic and treatment decisions. In particular, the BHA‐CS captured reliable decline in more individuals with MCI (44%) compared to the MoCA (20%). The BHA also demonstrated greater stability over 1‐year period compared to the MoCA, which is consistent with past reports on suboptimal longitudinal reliability of the MoCA in older adults.[^31^](#dad212042-bib-0031){ref-type="ref"}, [^32^](#dad212042-bib-0032){ref-type="ref"}

Longitudinal but not cross‐sectional performance on the BHA‐CS was sensitive to baseline Aβ‐PET in CN older adults. These findings are consistent with previous reports on Aβ‐related cognitive decline during preclinical stages of AD.[^37^](#dad212042-bib-0037){ref-type="ref"}, [^40^](#dad212042-bib-0040){ref-type="ref"} Implementation of highly sensitive cognitive measures that are able to capture cognitive changes in at‐risk older adults could help better characterize subtle cognitive changes during the preclinical period. Additionally, these findings provide preliminary support for future use of the BHA‐CS in secondary prevention trials with disease‐modifying agents given its potential to reliably detect treatment effects over time.

Our study has a number of limitations. First, our sample was largely comprised of highly educated, white participants and may not be representative of the general populations. At the same time, inclusion of Spanish‐speaking participants in our sample provided preliminary support for validity of the BHA‐CS in discriminating between cognitively intact and cognitively impaired individuals in ethnically diverse groups. Second, our cross‐validation procedure did not include a true external sample, which limits generalizability of these results. Data collection for culturally, linguistically, and educationally diverse external samples is ongoing. Also, our longitudinal sample of Aβ+ CN participants was relatively small (N = 29), and so these findings merit replication in a larger sample. Exploring associations with other neurodegenerative biomarkers (eg, tauPET, neurofilament light chain) will also be valuable in light of our findings on longitudinal sensitivity to decline in an etiologically diverse cognitively impaired group. Finally, the longitudinal analyses were based on roughly annual visits using the same versions of the BHA tests, while real‐life applications may require more frequent administrations using alternate forms, particularly in clinical trials.

In summary, the BHA‐CS is a novel cognitive composite measure based on a brief and easy to administer computerized battery that is optimized for the detection of cognitive impairment in older adults. Given its sensitivity to preclinical and prodromal stages of neurodegenerative disease, particularly AD, the BHA‐CS represents a valuable alternative to traditional brief cognitive assessments for clinical and research applications.
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